Effect of temperature on muscarinic cholinoceptor-mediated phosphoinositide metabolism and tension generation in bovine tracheal smooth muscle. 1994

E R Chilvers, and M A Giembycz, and R A Challiss, and G J Offer, and S R Nahorski
Department of Cell Physiology and Pharmacology, University of Leicester, UK.

The effect of decreased temperature on phosphoinositide metabolism was studied in flurbiprofen pretreated bovine tracheal smooth muscle (BTSM) by investigating the consequences of cooling on muscarinic-cholinoceptor-mediated [3H]inositol phosphate ([3H]InsP) and inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) accumulation, basal phosphoinositidase C (PIC) activity and airways smooth muscle (ASM) tone. Cooling of [3H]Ins labelled BTSM slices from 37 degrees C to 27 degrees C for 20 min prior to the addition of agonist caused a substantial (73.0 +/- 2.5%) inhibition of carbachol (100 microM, 30 min)-stimulated [3H]InsP accumulation compared to values measured at 37 degrees C. The degree of inhibition of [3H]InsP accumulation was similar at all agonist time points (2-30 min) studied. In parallel experiments, cooling of unlabelled BTSM slices from 37 degrees C to 27 degrees C resulted in a 34% reduction in basal Ins(1,4,5)P3 mass (37 degrees C, 13.1 +/- 0.6 pmol mg-1 protein; 27 degrees C, 8.9 +/- 0.9 pmol mg-1 protein; P < 0.02) and markedly attenuated carbachol (100 microM)-stimulated increases in Ins(1,4,5)P3 accumulation. Basal PIC activity in the soluble fraction of BTSM homogenates, measured using a [3H]phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) /deoxycholate assay system, was also significantly lower at 27 degrees C compared to 37 degrees C (initial velocities of PtdIns(4,5)P2 hydrolysis of 853 +/- 167 (37 degrees C) and 418 +/- 119 (27 degrees C) pmol min-1 ml-1 (1/400 diluted) BTSM cytosol; p < 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008455 (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride A drug that selectively activates certain subclasses of muscarinic receptors and also activates postganglionic nicotinic receptors. It is commonly used experimentally to distinguish muscarinic receptor subtypes. McN A-343,McN-A-343,McN-A343,McNeil A 343,A 343, McNeil,McN A 343,McN A343,McNA343
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D009130 Muscle, Smooth Unstriated and unstriped muscle, one of the muscles of the internal organs, blood vessels, hair follicles, etc. Contractile elements are elongated, usually spindle-shaped cells with centrally located nuclei. Smooth muscle fibers are bound together into sheets or bundles by reticular fibers and frequently elastic nets are also abundant. (From Stedman, 25th ed) Muscle, Involuntary,Smooth Muscle,Involuntary Muscle,Involuntary Muscles,Muscles, Involuntary,Muscles, Smooth,Smooth Muscles
D010716 Phosphatidylinositols Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to the hexahydroxy alcohol, myo-inositol. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid, myo-inositol, and 2 moles of fatty acids. Inositide Phospholipid,Inositol Phosphoglyceride,Inositol Phosphoglycerides,Inositol Phospholipid,Phosphoinositide,Phosphoinositides,PtdIns,Inositide Phospholipids,Inositol Phospholipids,Phosphatidyl Inositol,Phosphatidylinositol,Inositol, Phosphatidyl,Phosphoglyceride, Inositol,Phosphoglycerides, Inositol,Phospholipid, Inositide,Phospholipid, Inositol,Phospholipids, Inositide,Phospholipids, Inositol
D011976 Receptors, Muscarinic One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology. Muscarinic Acetylcholine Receptors,Muscarinic Receptors,Muscarinic Acetylcholine Receptor,Muscarinic Receptor,Acetylcholine Receptor, Muscarinic,Acetylcholine Receptors, Muscarinic,Receptor, Muscarinic,Receptor, Muscarinic Acetylcholine,Receptors, Muscarinic Acetylcholine
D002217 Carbachol A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS. Carbamylcholine,Carbacholine,Carbamann,Carbamoylcholine,Carbastat,Carbocholine,Carboptic,Doryl,Isopto Carbachol,Jestryl,Miostat,Carbachol, Isopto
D002417 Cattle Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor. Beef Cow,Bos grunniens,Bos indicus,Bos indicus Cattle,Bos taurus,Cow,Cow, Domestic,Dairy Cow,Holstein Cow,Indicine Cattle,Taurine Cattle,Taurus Cattle,Yak,Zebu,Beef Cows,Bos indicus Cattles,Cattle, Bos indicus,Cattle, Indicine,Cattle, Taurine,Cattle, Taurus,Cattles, Bos indicus,Cattles, Indicine,Cattles, Taurine,Cattles, Taurus,Cow, Beef,Cow, Dairy,Cow, Holstein,Cows,Dairy Cows,Domestic Cow,Domestic Cows,Indicine Cattles,Taurine Cattles,Taurus Cattles,Yaks,Zebus
D003080 Cold Temperature An absence of warmth or heat or a temperature notably below an accustomed norm. Cold,Cold Temperatures,Temperature, Cold,Temperatures, Cold
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

E R Chilvers, and M A Giembycz, and R A Challiss, and G J Offer, and S R Nahorski
February 1990, British journal of pharmacology,
E R Chilvers, and M A Giembycz, and R A Challiss, and G J Offer, and S R Nahorski
May 1999, European journal of pharmacology,
E R Chilvers, and M A Giembycz, and R A Challiss, and G J Offer, and S R Nahorski
July 1991, European journal of pharmacology,
E R Chilvers, and M A Giembycz, and R A Challiss, and G J Offer, and S R Nahorski
October 1992, British journal of pharmacology,
E R Chilvers, and M A Giembycz, and R A Challiss, and G J Offer, and S R Nahorski
January 1992, British journal of pharmacology,
E R Chilvers, and M A Giembycz, and R A Challiss, and G J Offer, and S R Nahorski
July 1974, Experientia,
E R Chilvers, and M A Giembycz, and R A Challiss, and G J Offer, and S R Nahorski
July 1998, The Journal of pharmacology and experimental therapeutics,
E R Chilvers, and M A Giembycz, and R A Challiss, and G J Offer, and S R Nahorski
January 1994, British journal of pharmacology,
E R Chilvers, and M A Giembycz, and R A Challiss, and G J Offer, and S R Nahorski
October 2002, Naunyn-Schmiedeberg's archives of pharmacology,
E R Chilvers, and M A Giembycz, and R A Challiss, and G J Offer, and S R Nahorski
January 1992, Biochemical pharmacology,
Copied contents to your clipboard!